Research

In a four-hour conversation, DeepMind's CEO makes the case that current scaling trajectories are being underestimated, and outlines what the next two years of AI development will look like. One of the most substantive interviews of the year.

A peer-reviewed study shows a 94% accuracy rate — 11 points above specialist average — with significantly lower false positive rates across all cohorts. Published in Nature.

A major update to AlphaFold extends its predictions beyond protein structures to drug binding sites. Pharmaceutical researchers say this could halve early-stage drug discovery timelines for certain disease classes.